Franklin Future of Health and Wellness UCITS ETF IE0003WEWAX4 Thematic | Factsheet as of 31 January 2025 This is a marketing communication. Please refer to the prospectus of the UCITS and to the KIID before making any finalFund Overview investment decisions. Umbrella Franklin Templeton ICAV This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Fund Base Currency USD Fund Inception Date 05/07/2023 Investment Overview Valor Number 127057322 The objective of the Fund is to provide exposure to companies that are involved in delivering sustainable products and ISIN IE0003WEWAX4 services related to health and wellness globally. The Fund seeks to track the performance of the Solactive Sustainable Bloomberg FOHW GY Health and Wellness Index (the “Index”) as closely as possible, regardless of whether the Index level rises or falls, while Domicile Ireland seeking to minimise as far as possible the tracking error between the Fund's performance and that of the Index. The UCITSYes Index is comprised of global equity securities issued by companies from developed markets and is designed to Product Structure Physical measure the equity performance of those companies that are utilising technology and demonstrating innovation within Replication Methodology Full Replication the healthcare industry as well as companies that are enabling access to care, health, or wellness provision for a wide Frequency of Index range of consumers including the elderly.Reconstitution Semiannually Use of IncomeAccumulation Past performance does not predict future returns. Fiscal Year End 30 June Shares Outstanding 100,000 Performance Over 1 Year (%) EU SFDR Category Article 8 Franklin Future of Health and Wellness UCITS ETF Solactive Sustainable Health and Wellness Index-NR (USD) Benchmark(s) and Type 125 Solactive Sustainable Health and Wellness 120 Index-NR Target 115 110 Charges Total Expense Ratio 0.30% 105 100 The charges are the fees the Fund charges to investors to cover the costs of running the Fund. Additional costs, including 95 transaction fees, will also be incurred. These costs are paid out by 01/24 04/2407/24 10/24 01/25 the Fund, which will impact on the overall return of the Fund. Fund charges will be incurred in multiple currencies, meaning that Discrete Annual Performance (%) payments may increase or decrease as a result of currency 01/2401/23 01/22 01/21 01/20 01/19 01/18 01/1701/16 01/15 exchange fluctuations. 01/2501/24 01/23 01/22 01/21 01/20 01/19 01/18 01/17 01/16 Fund 7.21 — — — — — — —— — Fund Characteristics Fund Target Benchmark 7.35 — — — — — — —— — Total Net Assets $2.70 Million Number of Holdings 93 93 Total Returns (%)Price to Book3.28x 3.66x Cumulative Average Annual Price to Earnings (12-MonthInception Trailing) 2.38x 26.35x 1-Mo 3-Mo YTD1-Yr 3-Yr 5-Yr Inception 3-Yr5-Yr Inception Date Return on Equity 12.99% 12.99% Fund Dividend Yield 1.42% 1.43% 6.621.84 6.62 7.21 — —9.56 —— 5.96 5/7/2023 Standard Deviation (1 Yr) 13.16% 13.16% Benchmark6.621.87 6.62 7.35 — —9.76 —— 6.08— The fund's returns may increase or decrease as a result of changes to foreign exchange rates. All performance data shown is in the fund's base currency. Performance data is based on the net asset value (NAV) of the ETF which may not be the same as the market price of the ETF. Individual investors may realise returns that are different to the NAV performance. Past performance does not predict future returns. The actual costs vary depending on the executing custodian. In addition, deposit costs may be incurred which could have a negative effect on the value. Please find out the costs due from the respective price lists from the processing/custodian bank. Changes in exchange rates could have positive or negative effects on this investment. Please visit https://www.franklinresources.com/all-sites for current performance and see the latest prospectus or supplement for further details. When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates maybe used between the portfolio and its benchmark. Franklin Future of Health and Wellness UCITS ETF as of 31 January 2025 Top Equity Issuers (% of Total) Trading Information Fund ExchangeTickerCurrencyBloombergReutersSEDOL ABBOTT LABORATORIES 3.57Borsa Italiana FOHW EUR FOHW IM FOHW.MI BMCJZ47 INTUITIVE SURGICAL INC 3.44Deutsche Börse XetraFOHW EUR FOHW GRFOHW.DE BMCJZ36 ELI LILLY & CO 3.06Euronext Paris Exchange FOHW EUR FOHW FP FOHW.PA BSLMY42 ABBVIE INC 3.01London Stock Exchange FRHW GBP FRHW LNFRHW.L BMCJZ81 ROCHE HOLDING AG 2.96London Stock Exchange FOHW USD FOHW LNFOHW.L BMCJZ70 ASTRAZENECA PLC 2.78SIX Swiss Exchange FOHW USD FOHW SW FOHW.S BMCJZ58 NOVARTIS AG 2.78 MERCK & CO INC 2.76Portfolio Management THERMO FISHER SCIENTIFIC INC 2.72Years with Firm Years of Experience BOSTON SCIENTIFIC CORP 2.63Lorenzo Crosato, CFA 7 26 Dina Ting, CFA9 29 Geographic Allocation (% of Total) What are the Risks? Fund Target United States 65.51 66.58Concentration risk: the risk that arises when a fund invests in relatively few holdings, few sectors or a restricted geographic area. Switzerland8.46 8.49Performance may be more volatile than a fund with a greater number of securities. Counterparty risk: the risk of failure of financial United Kingdom 4.47 4.50institutions or agents (when serving as a counterparty to financial contracts) to perform their obligations, whether due to insolvency, bankruptcy or other causes. Derivative Instruments risk: the risk of loss in an instrument where a small change in the value of the Australia 4.24 3.81 underlying investment may have a larger impact on the value of such instrument. Derivatives may involve additional liquidity, credit and Germany4.12 3.37 counterparty risks. Foreign Currency risk: the risk of loss arising from exchange-rate fluctuations or due to exchange control regulations. France 3.98 3.66Index related risk: the risk that quantitative techniques used in creating the Index the Fund seeks to track do not generate the intended Japan 3.48 3.49result, or that the portfolio of the Fund deviates from its Index composition or performance. Secondary market trading risk: the risk that Denmark3.19 3.20the shares purchased on the secondary market cannot usually be sold directly back to the Fund and that investors may therefore pay Others 2.41 2.90more than the NAV per share when buying shares or may receive less than the current NAV per Share when selling shares. The Fund does Cash & Cash Equivalents0.13 0.00not offer any capital guarantee or protection and you may not get back the amount invested. The Fund is subject to the following risks which are materially relevant: Complete information on the risks of investing in the Fund are set out in the Fund's prospectus. Sector Allocation (% of Total) Fund Glossary Health Care Equipment 30.72Total Expense Ratio: Total Expense Ratio (TER) includes the fees paid to the management company, the investment manager and the Pharmaceuticals 24.91depository, as well as certain other expenses. The TER is calculated by taking the relevant main material costs paid out over the 12-month Biotechnology11.32 period indicated and dividing them by the average net assets over the same period. The TER does not include all expenses paid by the fund (for example, it does not include what the fund pays for buying and selling securities). For a comprehensive list of the types of costs Life Sciences Tools & Services5.16 deducted from fund assets, see the prospectus. For recent all-in annual costs, as well as hypothetical performance scenarios that show Health Care Facilities 4.94 the effects that different levels of return could have on an investment in the fund, where applicable, see the KIID. Product Structure: The Health Care Services 3.65Product Structure indicates whether an ETF is holding physical securities (i.e. Physical) or whether it is tracking the index performance Education Services 2.65using derivatives (swaps, i.e. Synthetic). Methodology: The Methodology indicates whether an ETF is holding all index securities in the Health Care Technology2.24 same weight as the index (i.e. Physical Replication) or whether an optimised subset of index securities is used (i.e. Optimised) in order to Others 14.28efficiently track index performance. Target: The benchmark is defined in the objective as a target the Fund intends to meet or beat. Price Cash & Cash Equivalents 0.13 to Book: The price per share of a stock divided by its book value (i.e., net worth) per share. For a portfolio, the value represents a weighted average of the stocks it holds. Price to Earnings (12-Month Trailing) is the share price of a stock, divided by its per-share earnings over the past year. For a portfolio, the value represents a weighted average of the stocks it holds. Return on Equity: A measure of a Market Cap Breakdown (% of Equity) (USD) corporation's profitability that reveals how much profit a company generates with the money shareholders have invested. For a portfolio, Fund the value represents a weighted average of the stocks it holds. Dividend Yield is the annual dividend received on an equity security as a <2.0 Billion 9.14 percentage of the price. For a portfolio, the value represents a weighted average of the stocks it holds. It should not be used as an 2.0-5.0 Billion 8.99indication of the income received from this portfolio. Standard Deviation: Measure of the degree to which a fund's return varies from the average of its previous returns. The larger the standard deviation, the greater the likelihood (and risk) that a fund's performance will 5.0-10.0 Billion 5.38 fluctuate from the average return. 10.0-25.0 Billion11.85 25.0-50.0 Billion 8.93 Portfolio Data Information >50.0 Billion 55.71 Holdings are provided for information purposes only and should not be deemed a recommendation to buy or sell the securities mentioned. Franklin Future of Health and Wellness UCITS ETFas of 31 January 2025 Important Information This fund meets the requirements under Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR); the fund has binding commitments in its investment policy to promote environmental and/or social characteristics and any companies in which it invests should follow good governance practices. Further information in relation to the sustainability-related aspects of the Fund can be found at www.franklintempleton.lu/SFDR. Please review all of the Fund's objectives and characteristics before investing. This is a sub-fund ("Fund") of Franklin Templeton ICAV, an Irish collective asset-management vehicle. An investment in Franklin Templeton ICAV entails risks which are described in the latest prospectus or supplement and in the KIID. The Fund's documents are available in English, German and French from your local website or can be requested via FT's European Facilities Service available at www.eifs.lu/franklintempleton. In addition, a Summary of Investor Rights is available from www.franklintempleton.lu/summary-of-investor-rights. The summary is available in English. Franklin Templeton ICAV is notified for marketing in multiple EU Member States under the UCITS Directive. Franklin Templeton ICAV can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive. For the avoidance of doubt, if you decide to invest, you will be buying units/shares in the Fund and will not be investing directly in the underlying assets of the Fund. Given the variety of investment options available today, we suggest investors seek guidance from a Financial Adviser. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. © Morningstar, Inc. All rights reserved. The information contained here in (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Solactive AG ("Solactive") is the licensor of Solactive Sustainable Health and Wellness Index-NR (the "Index"). The financial instruments that are based on the Index are not sponsored, endorsed, promoted or sold by Solactive in any way and Solactive makes no express or implied representation, guarantee or assurance with regard to: (a) the advisability in investing in the financial instruments; (b) the quality, accuracy and/or completeness of the Index; and/or (c) the results obtained or to be obtained by any person or entity from the use of the Index. Solactive does not guarantee the accuracy and/or the completeness of the Index and shall not have any liability for any errors or omissions with respect thereto. Notwithstanding Solactive’s obligations to its licensees, Solactive reserves the right to change the methods of calculation or publication with respect to the Index and Solactive shall not be liable for any miscalculation of or any incorrect, delayed or interrupted publication with respect to the Index. Solactive shall not be liable for any damages, including, without limitation, any loss of profits or business, or any special, incidental, punitive, indirect or consequential damages suffered or incurred as a result of the use (or inability to use) of the Index. Net Returns (NR) include income net of tax withholding when dividends are paid. Indices are unmanaged, and one cannot invest directly in an index. They do not reflect any fees, expenses or sales charges. Important data provider notices and terms available at www.franklintempletondatasources.com. Issued by Franklin Templeton Investment Management Limited (FTIML) Registered office: Cannon Place, 78 Cannon Street, London EC4N 6HL.ßTIML is authorised and regulated by the Financial Conduct Authority. UK Freephone: 0800 305 306 | email: enquiries@franklintempleton.co.uk | www.franklintempleton.co.uk